You are here: Industry Insights > Vaxart

News List

COVID-19 vaccine tablet induces systemic and mucosal immune responses europeanpharmaceuticalreview
September 23, 2020
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
Oral COVID-19 vaccine candidate to enter Phase I human trials europeanpharmaceuticalreview
September 17, 2020
Vaxart’s application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
Vaxart Signs MoU with AMS contractpharma
July 02, 2020
Partnership enables production of one billion or more COVID-19 vaccine doses per year.
Kindred, Vaxart Enter COVID-19 Vaccine Manufacturing Pact contractpharma
May 26, 2020
Kindred Biosciences has entered into an agreement with Vaxart for the manufacture of Vaxart's oral vaccine candidate for COVID-19.
Emergent BioSolutions and Vaxart partner on oral coronavirus vaccine pharmaceutical-technology
March 20, 2020
Emergent BioSolutions has agreed to provide molecule-to-market contract development and manufacturing (CDMO) services for Vaxart’s oral vaccine candidate against Covid-19 coronavirus infection.
Emergent, Vaxart Ink Coronavirus Pact contractpharma
March 19, 2020
Sign development and manufacturing agreement for experimental oral vaccine candidate.
Vaxart touts head-to-head data for oral flu vaccine versus Sanofi's Fluzone fiercepharma
November 09, 2018
Aiming to challenge flu shot market leader Sanofi, Vaxart put up phase 2 data for an oral flu vaccine candidate that the biotech says provided participants both mucosal
Vaxart Announces $5 Million Inavir® Revenue Milestone biospace
April 23, 2018
Vaxart, Inc.announced today that it received notification from Daiichi Sankyo Co., Ltd

Previous page 1 2 Next page